IL165022A0 - Formulations containing amiodarone and sulfoalkyl ether cyclodextrin - Google Patents
Formulations containing amiodarone and sulfoalkyl ether cyclodextrinInfo
- Publication number
- IL165022A0 IL165022A0 IL16502203A IL16502203A IL165022A0 IL 165022 A0 IL165022 A0 IL 165022A0 IL 16502203 A IL16502203 A IL 16502203A IL 16502203 A IL16502203 A IL 16502203A IL 165022 A0 IL165022 A0 IL 165022A0
- Authority
- IL
- Israel
- Prior art keywords
- formulations containing
- sulfoalkyl ether
- ether cyclodextrin
- containing amiodarone
- amiodarone
- Prior art date
Links
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005260 amiodarone Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
- 125000004964 sulfoalkyl group Chemical group 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,620 US6869939B2 (en) | 2002-05-04 | 2002-05-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| PCT/US2003/013250 WO2003092590A2 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165022A0 true IL165022A0 (en) | 2005-12-18 |
Family
ID=29399340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16502203A IL165022A0 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| IL165022A IL165022A (en) | 2002-05-04 | 2004-11-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165022A IL165022A (en) | 2002-05-04 | 2004-11-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6869939B2 (sl) |
| EP (2) | EP2402008B1 (sl) |
| JP (2) | JP4764004B2 (sl) |
| KR (1) | KR100984197B1 (sl) |
| AT (1) | ATE535239T1 (sl) |
| AU (1) | AU2003234285B2 (sl) |
| CA (1) | CA2483774C (sl) |
| CY (1) | CY1112527T1 (sl) |
| DK (2) | DK1501496T3 (sl) |
| ES (2) | ES2378306T3 (sl) |
| HU (1) | HUE027551T2 (sl) |
| IL (2) | IL165022A0 (sl) |
| MX (1) | MXPA04010925A (sl) |
| PT (1) | PT1501496E (sl) |
| SI (2) | SI2402008T1 (sl) |
| WO (1) | WO2003092590A2 (sl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1713504T1 (sl) | 2004-01-30 | 2017-10-30 | Zoetis Services Llc | Protimikrobni konzervansi za dosego večodmerne formulacije z uporabo beta-ciklodekstrinov za tekoče odmerne oblike |
| AU2005237523A1 (en) | 2004-04-23 | 2005-11-10 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
| EP1766037B1 (en) | 2004-05-12 | 2015-07-01 | Transworld Technologies Limited | Generation of hydrogen from hydrocarbon-bearing materials |
| US7426960B2 (en) | 2005-05-03 | 2008-09-23 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7416879B2 (en) | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
| KR20090010953A (ko) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
| KR20160033796A (ko) | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US7696132B2 (en) | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US20080194519A1 (en) * | 2006-09-15 | 2008-08-14 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090270496A1 (en) * | 2007-05-03 | 2009-10-29 | Courchesne William E | Antifungal compounds |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US8479813B2 (en) | 2009-12-16 | 2013-07-09 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| WO2011156481A2 (en) | 2010-06-11 | 2011-12-15 | Baxter International Inc. | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| CN103781484A (zh) | 2011-07-20 | 2014-05-07 | 赫思公司 | 治疗疼痛的方法 |
| KR101922752B1 (ko) * | 2011-11-29 | 2018-11-27 | 주록스 피티와이 리미티드 | 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법 |
| CA2861077A1 (en) * | 2012-01-30 | 2013-08-08 | Baxter International Inc. | Non-anticoagulant sulfated or sulfonated polysaccharides |
| CN104271605B (zh) | 2012-02-15 | 2017-07-25 | 锡德克斯药物公司 | 环糊精衍生物的制造方法 |
| JP2015508846A (ja) | 2012-02-28 | 2015-03-23 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| US9004162B2 (en) | 2012-03-23 | 2015-04-14 | Transworld Technologies Inc. | Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material |
| CN104780925A (zh) * | 2012-10-17 | 2015-07-15 | 赛博尔泰克股份公司 | 用于治疗多发性骨髓瘤的花青素络合物 |
| BR112015008954B1 (pt) | 2012-10-22 | 2021-03-02 | Cydex Pharmaceuticals, Inc | processos para preparar uma composição de ciclodextrina alquilatada compreendendo uma ciclodextrina alquilatada, para preparar pelo menos 9 lotes consecutivos da mesma e para preparar uma composição farmacêutica |
| KR102147084B1 (ko) * | 2012-11-15 | 2020-08-24 | 자피오텍 게엠베하 | 소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제 |
| EP2773033B1 (en) | 2013-02-28 | 2018-12-05 | Dialog Semiconductor GmbH | Divide by 2 and 3 charge pump methods |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| FI3183295T3 (fi) | 2014-08-22 | 2023-09-25 | Cydex Pharmaceuticals Inc | Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi |
| US10736891B2 (en) * | 2016-01-07 | 2020-08-11 | Roy MADIGAN | Composition and method for treating chagas disease |
| WO2017149552A1 (en) * | 2016-03-04 | 2017-09-08 | Sun Pharmaceutical Industries Ltd. | Parenteral dosage form of amiodarone |
| CN107753439A (zh) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | 一种注射用盐酸胺碘酮及其制备方法 |
| EP3541364A1 (en) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
| US10973780B2 (en) * | 2019-05-15 | 2021-04-13 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
| EP4010031A1 (en) | 2019-08-06 | 2022-06-15 | L.E.A.F Holdings Group LLC | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN115969833A (zh) * | 2023-01-03 | 2023-04-18 | 上海上药第一生化药业有限公司 | 胺碘酮药物组合物、注射液及其制备方法及含其的注射器 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0491812A4 (en) | 1989-09-14 | 1992-11-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| US5234949A (en) | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
| FR2735978B1 (fr) | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| EP1143796A4 (en) | 1999-01-21 | 2002-03-20 | Bristol Myers Squibb Co | RAS-FARNESYLTRANSFERASE AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXPROPYL-BETA-CYCLODEXTRIN INHIBITOR COMPLEX AND METHOD |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
-
2002
- 2002-05-04 US US10/139,620 patent/US6869939B2/en not_active Expired - Lifetime
-
2003
- 2003-04-29 KR KR1020047017639A patent/KR100984197B1/ko active IP Right Grant
- 2003-04-29 IL IL16502203A patent/IL165022A0/xx unknown
- 2003-04-29 PT PT03728598T patent/PT1501496E/pt unknown
- 2003-04-29 AU AU2003234285A patent/AU2003234285B2/en not_active Expired
- 2003-04-29 ES ES03728598T patent/ES2378306T3/es not_active Expired - Lifetime
- 2003-04-29 DK DK03728598.8T patent/DK1501496T3/da active
- 2003-04-29 JP JP2004500775A patent/JP4764004B2/ja not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013250 patent/WO2003092590A2/en active Application Filing
- 2003-04-29 SI SI200332474A patent/SI2402008T1/sl unknown
- 2003-04-29 MX MXPA04010925A patent/MXPA04010925A/es active IP Right Grant
- 2003-04-29 EP EP11182697.0A patent/EP2402008B1/en not_active Expired - Lifetime
- 2003-04-29 AT AT03728598T patent/ATE535239T1/de active
- 2003-04-29 EP EP03728598A patent/EP1501496B1/en not_active Expired - Lifetime
- 2003-04-29 CA CA2483774A patent/CA2483774C/en not_active Expired - Lifetime
- 2003-04-29 SI SI200332113T patent/SI1501496T1/sl unknown
- 2003-04-29 ES ES11182697.0T patent/ES2567716T3/es not_active Expired - Lifetime
- 2003-04-29 DK DK11182697.0T patent/DK2402008T3/en active
- 2003-04-29 HU HUE11182697A patent/HUE027551T2/en unknown
-
2004
- 2004-11-04 IL IL165022A patent/IL165022A/en active IP Right Grant
-
2011
- 2011-03-07 JP JP2011048873A patent/JP5656692B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-23 CY CY20121100190T patent/CY1112527T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003234285A1 (en) | 2003-11-17 |
| IL165022A (en) | 2011-08-31 |
| US6869939B2 (en) | 2005-03-22 |
| JP2011116776A (ja) | 2011-06-16 |
| PT1501496E (pt) | 2012-02-20 |
| EP2402008A1 (en) | 2012-01-04 |
| AU2003234285B2 (en) | 2007-01-04 |
| CA2483774C (en) | 2011-07-19 |
| ES2378306T3 (es) | 2012-04-11 |
| EP1501496A2 (en) | 2005-02-02 |
| JP2005530744A (ja) | 2005-10-13 |
| JP5656692B2 (ja) | 2015-01-21 |
| ATE535239T1 (de) | 2011-12-15 |
| WO2003092590A3 (en) | 2004-01-22 |
| US20030216353A1 (en) | 2003-11-20 |
| CA2483774A1 (en) | 2003-11-13 |
| HUE027551T2 (en) | 2016-10-28 |
| WO2003092590A2 (en) | 2003-11-13 |
| SI2402008T1 (sl) | 2016-05-31 |
| ES2567716T3 (es) | 2016-04-26 |
| DK2402008T3 (en) | 2016-05-02 |
| KR20040106452A (ko) | 2004-12-17 |
| CY1112527T1 (el) | 2015-12-09 |
| EP1501496A4 (en) | 2006-05-31 |
| DK1501496T3 (da) | 2012-03-19 |
| EP2402008B1 (en) | 2016-01-27 |
| MXPA04010925A (es) | 2005-02-14 |
| KR100984197B1 (ko) | 2010-09-28 |
| SI1501496T1 (sl) | 2012-04-30 |
| EP1501496B1 (en) | 2011-11-30 |
| JP4764004B2 (ja) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165022A0 (en) | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | |
| AU2002325856A1 (en) | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue | |
| WO2003028802A3 (en) | Devices for treating atrial fibrilation | |
| EP1465492A4 (en) | LIQUID COMPOSITION FOR PROMOTING PLANT GROWTH CONTAINING NANOPARTICULAR TITANIUM DIOXIDE | |
| PL1643833T3 (pl) | Formulacje agrochemiczne | |
| EP1496878A4 (en) | TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS | |
| HK1078466A1 (en) | Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance | |
| MXPA05013232A (es) | Composicion en forma de pulverizador que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa no volatil. | |
| IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
| WO2001078702A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| HUP0204399A3 (en) | Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use | |
| CY1107942T1 (el) | Ψεκασιμη συνθεση για τη χορηγηση παραγωγων της βιταμινης d | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| IL172423A0 (en) | Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | |
| WO2000066528A3 (en) | Quinones for treatment of diseases | |
| WO2001078703A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| EP1896035A4 (en) | CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS | |
| EP1248792A4 (en) | ANTISENSE MODULATION OF GAMMA RECEPTOR ACTIVE PEROXYSOME PROLIFERATION (PPAR) EXPRESSION | |
| WO2005046599A3 (en) | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | |
| WO2004098522A3 (en) | Gemini vitamin d3 compounds and methods of use thereof | |
| NO20060655L (no) | 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn | |
| HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
| IL150527A0 (en) | Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives | |
| MXPA03006626A (es) | Formulacion de la goma para el tratamiento de la semilla de plantas. | |
| AU2002235202A1 (en) | Treatment of bone disorders by modulation of fgfr3 |